All In Biotech

Drug Trial Radar · NCT02981368

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)

Last checked: Nov 19, 2026Latest source record: Aug 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

385

Actual

Start

Nov 2016

Primary completion

Jul 2018

Study completion Jul 2018

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B). Cohort B is complete and no longer recruiting subjects.

Conditions

  • Prostate Cancer

Interventions

  • 18F-DCFPyL InjectionDrug

    A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL

  • PET/CT imagingDiagnostic test

    PET/CT imaging will be acquired 1-2 hours post-PyL injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
  2. Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California at San Francisco (UCSF) - Mt. Zion Hospital

    San Francisco, California

  • Yale University Department of Radiology and Biomedical Imaging

    New Haven, Connecticut

  • University of Chicago

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Cancer Center

    Ann Arbor, Michigan

  • Washington University Mallinckrodt Institute of Radilogy

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Centre Hospitalier Universitaire de Quebec (CHUQ)

    Québec, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.